A Phase 4 interventional study of Valsartan/aliskiren and Valsartan in Stage 2 Hypertension, sponsored by Novartis. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-02.
Sponsored by Novartis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 43rd largest by enrollment of the 139 interventional ones that give a count, is one of 7 that started in 2009, is one of 67 in phase 4, and was the 97th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 7 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 451 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 86th largest by enrollment of the 222 interventional ones that give a count, is one of 17 that started in 2009, is one of 67 in phase 4, and was the 154th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of the valsartan/aliskiren combination compared to valsartan alone in patients with Stage 2 hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Valsartan/aliskiren
Drug: Valsartan
Drug pages: Valsartan · Aliskiren
Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8
To compare the change from baseline in MSSBP after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.
Time frame: Baseline to Week 8
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8
To compare the change in MSDBP after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan (160 mg, 320 mg) treatment regimen in patients with Stage 2 Hypertension.
Time frame: Baseline to Week 8
Percentage of Patients Achieving Blood Pressure Control (Defined as Patients Achieving a MSSBP <140 mmHg and MSDBP <90 mmHg) at Week 8
To evaluate the percentage of patients achieving blood pressure control (defined as patients achieving a MSSBP \<140 mmHg and MSDBP \<90 mmHg) at week 8 following treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.
Time frame: At Week 8
Percentage of Responders (Defined as Patients With MSSBP <140 mmHg or a Decrease From Baseline ≥20 mmHg) at Week 8
To compare the percentage of responders (defined as patients with MSSBP \<140 mmHg or a decrease from baseline ≥20 mmHg) at week 8 following treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.
Time frame: At Week 8
Mean Change From Baseline in Plasma Renin Activity (PRA) at Week 8
To assess the change from baseline in PRA after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.
Time frame: Baseline to Week 8
Mean Change From Baseline in Plasma Renin Concentration (PRC) at Week 8
To assess the change from baseline in PRC after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.
Time frame: Baseline to Week 8
Completers Analysis for Change From Baseline in MSSBP at Week 8
To evaluate the change from baseline in MSSBP (mmHg) at Week 8; primary efficacy variable at primary time point in ITT population - patients who completed the double-blind treatment period.
Time frame: Baseline to week 8
Longitudinal Repeated Measure Analysis for Change in MSSBP From Baseline Through Week 8
To evaluate the change from baseline in MSSBP (mmHg) after 8 weeks; primary efficacy variable (ITT population) using Longitudinal analysis (A repeated measures analysis where assessments over time are considered , as opposed to looking at a single point in time.)
Time frame: Baseline through week 8
Change From Baseline in Mean Ambulatory Systolic Blood Pressure (MASBP).
To evaluate 24-hour ambulatory systolic blood pressure measurements in a subset of patients after 8 weeks of treatment with the combination of valsartan and aliskiren versus valsartan monotherapy in patients with stage 2 hypertension.
Time frame: Baseline to week 8
Change From Baseline in Mean Ambulatory Diastolic Blood Pressure (MADBP)
To evaluate 24-hour ambulatory diastolic blood pressure measurements in a subset of patients after 8 weeks of treatment with the combination of valsartan and aliskiren versus valsartan monotherapy in patients with stage 2 hypertension.
Time frame: Baseline to week 8
| Milestone | Valsartan/Aliskiren | Valsartan |
|---|---|---|
| Started | 232 | 219 |
| Completed | 201 | 196 |
| Not completed | 31 | 23 |
| Withdrew: Adverse event | 18 | 10 |
| Withdrew: Unsatisfactory therapeutic effect | 3 | 3 |
| Withdrew: Patient withdrew consent | 8 | 6 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Administrative problems | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 2 |
To compare the change from baseline in MSSBP after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.
| mm Hg | Valsartan/Aliskiren | Valsartan |
|---|---|---|
| Baseline | 164.8 ± 4.54 | 166.2 ± 5.23 |
| Week 8 | 142.3 ± 17.01 | 145.6 ± 17.55 |
| Change from Baseline to Week 8 | -22.5 ± 16.04 | -20.6 ± 16.25 |
To compare the change in MSDBP after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan (160 mg, 320 mg) treatment regimen in patients with Stage 2 Hypertension.
| mm Hg | Valsartan/Aliskiren | Valsartan |
|---|---|---|
| Baseline | 93.9 ± 8.22 | 94.8 ± 8.68 |
| Week 8 | 85.7 ± 10.94 | 86.4 ± 10.34 |
| Change from Baseline to Week 8 | -8.2 ± 9.77 | -8.3 ± 9.49 |
To evaluate the percentage of patients achieving blood pressure control (defined as patients achieving a MSSBP \<140 mmHg and MSDBP \<90 mmHg) at week 8 following treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.
| percentage of patients | Valsartan/Aliskiren | Valsartan |
|---|---|---|
| Percentage of Patients Achieving Blood Pressure Control (Defined as Patients Achieving a MSSBP <140 mmHg and MSDBP <90 mmHg) at Week 8 | 44.3 | 36.2 |
To compare the percentage of responders (defined as patients with MSSBP \<140 mmHg or a decrease from baseline ≥20 mmHg) at week 8 following treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.
| percentage of responders | Valsartan/Aliskiren | Valsartan |
|---|---|---|
| Percentage of Responders (Defined as Patients With MSSBP <140 mmHg or a Decrease From Baseline ≥20 mmHg) at Week 8 | 64.7 | 53.1 |
To assess the change from baseline in PRA after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.
| ng/mL/h | Valsartan/Aliskiren | Valsartan |
|---|---|---|
| Baseline | 0.992 ± 1.290 | 0.831 ± 0.854 |
| Week 8 | 0.436 ± 0.659 | 2.450 ± 3.73 |
| Change from Baseline to Week 8 | -0.540 ± 1.285 | 1.577 ± 3.528 |
To assess the change from baseline in PRC after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.
| ng/L | Valsartan/Aliskiren | Valsartan |
|---|---|---|
| Baseline | 8.286 ± 10.893 | 8.065 ± 14.932 |
| Week 8 | 142.833 ± 293.228 | 20.089 ± 31.771 |
| Change from Baseline to Week 8 | 135.515 ± 296.758 | 11.988 ± 32.679 |
To evaluate the change from baseline in MSSBP (mmHg) at Week 8; primary efficacy variable at primary time point in ITT population - patients who completed the double-blind treatment period.
| mm Hg | Valsartan/Aliskiren | Valsartan |
|---|---|---|
| Baseline | 164.8 ± 4.54 | 166.2 ± 5.23 |
| Week 8 | 140.9 ± 15.74 | 145.9 ± 16.89 |
| Change from Baseline to Week 8 | -24.0 ± 14.70 | -20.3 ± 15.49 |
To evaluate the change from baseline in MSSBP (mmHg) after 8 weeks; primary efficacy variable (ITT population) using Longitudinal analysis (A repeated measures analysis where assessments over time are considered , as opposed to looking at a single point in time.)
| mm Hg | Valsartan/Aliskiren | Valsartan |
|---|---|---|
| Longitudinal Repeated Measure Analysis for Change in MSSBP From Baseline Through Week 8 | -23.2 ± 1.04 | -20.1 ± 1.08 |
To evaluate 24-hour ambulatory systolic blood pressure measurements in a subset of patients after 8 weeks of treatment with the combination of valsartan and aliskiren versus valsartan monotherapy in patients with stage 2 hypertension.
| mm Hg | Valsartan/Aliskiren | Valsartan |
|---|---|---|
| Baseline | 146.1 ± 9.14 | 143.5 ± 14.10 |
| Week 8 | 130.3 ± 13.41 | 137.6 ± 17.11 |
| Change from Baseline to Week 8 | -15.8 ± 11.42 | -6.0 ± 13.34 |
To evaluate 24-hour ambulatory diastolic blood pressure measurements in a subset of patients after 8 weeks of treatment with the combination of valsartan and aliskiren versus valsartan monotherapy in patients with stage 2 hypertension.
| mm Hg | Valsartan/Aliskiren | Valsartan |
|---|---|---|
| Baseline | 87.9 ± 7.28 | 85.7 ± 9.26 |
| Week 8 | 78.2 ± 9.44 | 81.7 ± 10.11 |
| Change from Baseline to Week 8 | -9.7 ± 7.02 | -4.0 ± 8.09 |
Collected over Baseline through week 8. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan/ Aliskiren | — | 5/232 (2.2%) | 14/232 (6%) |
| Valsartan | — | 3/219 (1.4%) | 15/219 (6.8%) |
| Event | Valsartan/ Aliskiren | Valsartan |
|---|---|---|
| Non-cardiac chest painGeneral disorders | 2/232 | 0/219 |
| DehydrationMetabolism and nutrition disorders | 2/232 | 0/219 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/232 | 1/219 |
| AnaesthesiaNervous system disorders | 0/232 | 1/219 |
| HemiparesisNervous system disorders | 0/232 | 1/219 |
| AnxietyPsychiatric disorders | 0/232 | 1/219 |
| Confusional statePsychiatric disorders | 0/232 | 1/219 |
| Conversion disorderPsychiatric disorders | 0/232 | 1/219 |
| Deep vein thrombosisVascular disorders | 0/232 | 1/219 |
| LymphocytosisBlood and lymphatic system disorders | 1/232 | 0/219 |
| Event | Valsartan/ Aliskiren | Valsartan |
|---|---|---|
| HeadacheNervous system disorders | 14/232 | 15/219 |
| Age Continuous(years) | Valsartan/Aliskiren | Valsartan | Total |
|---|---|---|---|
| Mean | 57.5 ± 11.1 | 56.7 ± 11.0 | 57.1 ± 11.0 |
| Sex: Female, Male(Participants) | Valsartan/Aliskiren | Valsartan | Total |
|---|---|---|---|
| Female | 107 | 116 | 223 |
| Male | 125 | 103 | 228 |
The record gives a start of Jan 2009, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Aliskiren